READY-TO-GO FORMULATION PIPELINE

Helping Patients Feel Like People

Long Acting Injectable Formulations Available for License

Qrono has developed an extensive internal pipeline of long-acting drug formulations in the following therapeutic areas:

 PSYCHIATRY  |  ONCOLOGY  |  MEDICAL COUNTERMEASURES  |  MUSCULOSKELETAL  |  INFECTIOUS DISEASE |  ENDOCRINOLOGY

 

Formulation Pipeline Details

INDICATION PROGRAM API DURATION MARKET IN SILICO IN VITRO CLINICAL
Psychiatry QR901 Generic Risperdal®Consta®
14-day
$1.4B
 
ANDA
QR106 Risperidone Qx™
60-day
$1.4B
   
505(b)(2)
QR103 Quetiapine Qx™
28-day
$2.5B
 
505(b)(2)
QR110 PROPRIETARY  28-day      505(b)(2)
QR113 PROPRIETARY  28-day  $2.4B 505(b)(2)
QR114 PROPRIETARY   28-day  $1.3B  505(b)(2)
Oncology QR902 Generic Sandostatin®LAR
28-day
$1.6B
 
ANDA
QR904 Generic Lupron Depot®  28-day  $1.7B  ✓   ✓    ANDA
QR107 Octreotide Qx™
90-day
$1.5B
  505(b)(2)
QR206 Epothilone D Qx™ (Locally-Acting)
45-day
$1.9B
505(b)(2)
QR207 Paclitaxel Qx™ (Locally-Acting)
45-day
$3.6B
     505(b)(2)
QR210

Vinorelbine + Cisplatin combo (Locally-Acting)

 45-day
$1.9B
    505(b)(2)
QR212

Doxorubicin

45-day  $1.9B  505(b)(2)
QR213

PROPRIETARY

Medical Countermeasures QR205 Butyrylcholinesterase Qx™
20-day
$2.6B
505(b)(2)
QR215

Levocetirizine + Montelukast

7-day
 505(b)(2)
Musculoskeletal QR111 PROPRIETARY      
505(b)(2)
Infectious Disease QR109 Anti-Tuberculosis Combo
60-day
$600M
    505(b)(2)
QR211 Dengue Vaccine
$1.0B
 ✓  
QR112 HIV PrEP 28-day
$1.9B
505(b)(2)
Endocrinology QR903 Generic Bydureon®
7-day
$580M
  ANDA
QR108 Exenatide Qx™
14-day
$580M
  505(b)(2)

Products under patent are not for ultimate sale in countries where relevant patents have not expired.

“Our product pipeline has gone through extensive in silico optimization using our QronoMetrics™ system.  The majority have positive in vitro study data available, and have been validated against in vivo data where available.  These licensing opportunities leverage off-patent APIs and PLGA microspheres, address multiple indications where long-acting formulations add therapeutic and pharmacoeconomic value, and can strengthen your product portfolio.”

— Larry Zana, CEO, Qrono, Inc.

Contact Us

Send us an email and we'll get back to you ASAP! Thanks